Helicobacter pylori infection and antisecretory efficacy of proton-pump inhibitors in gastroesophageal reflux disease: A liaison dangereuse or an innocent interplay?

References

• El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43: 327–33
   PubMed Web of Science ®Google Scholar
• Locke GR, Talley NJ, Fett SL, Zinmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted county. Minnesota Gastroenterol 1997; 112: 1448–56
   PubMed Web of Science ®Google Scholar
• Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9 Suppl 2: 45–51
   PubMedGoogle Scholar
• Ho KY, Chan YH, Kang JK. Increasing incidence of reflux esophagitis and decreasing trend of Helicobacter pylori infection in patients from a multiethnic Asian country. Am J Gastroenterol 2005; 100: 1923–8
   PubMed Web of Science ®Google Scholar
• Labenz J, Blum AL, Bayerdorffer A, Meining A, Stolte M, Borson G, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442–7
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Lundell L, Klikenberg-Knol EC. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018–22
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O'Morain C. Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 1997; 41: 8–13
   PubMed Web of Science ®Google Scholar
• Abbas Z, Hussainy AS, Ibrahim F, Jafri SM, Shaikh H, Khan AH. Barrett's oesophagus and Helicobacter pylori. J Gastroenterol Hepatol 1995; 10: 331–3
   PubMedGoogle Scholar
• Young MA, Kim R, Clark MR, Van Bibber MM, Saflate-Ribeiro AV, Ribeiro U, et al. The incidence of premalignant markers of oesophageal cancer is increased in Barrett's patients with Helicobacter pylori. Gastroenterology 1996; 110 Suppl: A618
   Google Scholar
• Verdu EF, Armstrong D, Fraser R, Viani F, Lostron JP, Coderberg C, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539–43
   PubMed Web of Science ®Google Scholar
• Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11–6
   PubMed Web of Science ®Google Scholar
• Carlsson R, Bate C, Dent J, et al. Does H. pylori infection influence the response to treatment with acid inhibition in patients with GERD?. Scand J Gastroenterol 1997; 32 Suppl 224: F70
   Google Scholar
• Raghunath A, Hungin AP, Woof D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. Br Med J 2005; 326: 737–43
   Google Scholar
• Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori. Gut 1993; 34: 888–92
   PubMed Web of Science ®Google Scholar
• El-Omar EM, Penman ID, Ardill IE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109: 681–91
   PubMed Web of Science ®Google Scholar
• Parente F, Maconi G, Sangaletti O, Minguzzi M, Vago L, Bianchi Porro G. Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of Helicobacter pylori in duodenal ulcer patients. A controlled study. Gut 1995; 37: 210–5
   PubMed Web of Science ®Google Scholar
• Gutierrez O, Melo M, Segura AM, Angel A, Genta R, Graham DY. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997; 32: 664–8
   PubMed Web of Science ®Google Scholar
• Haruma K, Mihara M, Kusunoki H, Hananoki M, Tanaka S, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus: evaluation of 24-hour pH monitoring. Gut 1999; 13: 155–62
   Google Scholar
• Feldman M, Cryer B, Sammer D, Lee E, Spechler SJ. Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. Am J Physiol 1999; 277: G1159–64
   Google Scholar
• Tefera S, Hatlebakk JG, Berstad A. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther 1999; 13: 915–20
   PubMedGoogle Scholar
• Manes G, Esposito P, Lioniello M, Bove A, Mosca S, Balzano A. Manometric and pH-metric features in gastroesophageal reflux disease patients with and without Helicobacter pylori infection. Dig Liver Dis 2000; 32: 372–7
   PubMedGoogle Scholar
• Manifold DK, Anggiansah A, Rowe I, Sanderson JD, Chinyama CN, Owen WJ. Gastro-esophageal reflux and duodenogastric reflux before and after eradication in Helicobacter pylori gastritis. Eur J Gastroenterol Hepatol 2001; 13: 535–9
   PubMedGoogle Scholar
• Verma S, Jackson W, Floum S, Giaffer MH. Gastroesophageal reflux before and after Helicobacter pylori eradication. A prospective study using ambulatory 24-h esophageal pH monitoring. Dis Esophagus 2003; 16: 273–8
   PubMedGoogle Scholar
• Wu JC, Chan FK, Ching JY, Leung WK, Hui Y, Leong R, et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo-controlled, randomised trial. Gut 2004; 53: 174–9
   PubMed Web of Science ®Google Scholar
• Cedeberg C, Thomson AB, Mahachai V, Westin JA, Kirdeikis P, Fisher S, et al. Effects of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology 1992; 103: 913–8
   PubMedGoogle Scholar
• Cedeberg C, Rohss K, Lundborg P, Olbe L. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects. Scand J Gastroenterol 1993; 28: 179–84
   PubMedGoogle Scholar
• Labenz J, Tillenburg B, Peitz U, Idstron JP, Verdu EF, Stolte M, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725–32
   PubMed Web of Science ®Google Scholar
• Van Herwaarden MA, Samson M, Van Nispen CHM. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 1999; 13: 731–40
   PubMedGoogle Scholar
• Giral A, Celikel CA, Ozdogan O, Tozun N, Ulusoy NB, Kalayci C. Impact of Helicobacter pylori eradication on the antisecretory efficacy of lansoprazole in gastroesophageal reflux disease patients. J Gastroenterol Hepatol 2005; 20: 1886–91
   PubMedGoogle Scholar
• Labenz J, Tillenburg B, Peitz U, Borsch G, Idstrom JP, Verdu E, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997; 92: 576–8
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Uyterlinde AM, Pena AS, Hazeberg HJ, Bloemena E, Linderman, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implication for long-term safety. Am J Gastroenterol 1995; 90: 1401–6
   PubMed Web of Science ®Google Scholar
• Pfeiffer A, Kromer W, Friemann J, Ruge M, Herawi M, Schatzl M, et al. Muscarinic receptors in gastric mucosa are increased in peptic ulcer disease. Gut 1995; 36: 813–8
   PubMedGoogle Scholar
• O'Connor HJ. Review article: Helicobacter pylori and gastro-oesophageal reflux disease: clinical implications and management. Aliment Pharmacol Ther 1999; 13: 117–27
   PubMedGoogle Scholar
• Lambert JR, Midolo P, Prichard PJ, Savage J, Bampton P. Helicobacter pylori infection causes hypergastrinaemia during omeprazole therapy. Gut 1995; 37 Suppl 1: A59
   Google Scholar
• Labenz J, Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor?. Gut 1997; 41: 277–80
   PubMed Web of Science ®Google Scholar
• Hatlebakk, JG, Hyggen, A, Madsen, PH, Walle, PO, Schulz, T, Mowinckel, P, , et al. Heartburn treatment in primary care: randomized,double-blind study for 8 weeks. Br Med J 1999;319–553.
   Google Scholar
• Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease: an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003; 18: 767–76
   PubMed Web of Science ®Google Scholar
• Calleja, JL, Suarez, M, De Tejada, AH, and the Pantogerd Group. Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole. Dig Dis Sci 2005;50:432–9.
   PubMedGoogle Scholar
• Klikenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 2000; 118: 661–9
   PubMedGoogle Scholar
• Kuipers EJ, Nelis GF, Klikenberg-Knol EC, Snel P, Goldfain D, Kolman JJ, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long-term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53: 12–20
   PubMed Web of Science ®Google Scholar
• Vakil NB, Traxler BM, Levine D. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. Am J Gastroenterol 2004; 99: 1437–41
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Lind T, Willich S, Vieth M, Jaspersen D, Labenz J, et al. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005; 54: 746–51
   PubMed Web of Science ®Google Scholar
• de Boer W, de Wit N, Geldof H, Hazelhoff B, Bergmans P, Smout A, et al. Does Helicobacter pylori infection influence response rate or speed of symptom control in GERD patients treated with rabeprazole?. Scand J Gastroenterol 2006; 41: 000–00
   Google Scholar
• Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schutze K, et al. EXPO study investigators. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO Study. Aliment Pharmacol Ther 2005; 21: 739–46
   PubMed Web of Science ®Google Scholar